Dr. Jin Wang obtained his Ph.D. degree in Organic Chemistry from the Ohio State University with Dr. Matthew Platz in 2007, where he applied ultrafast spectroscopy to study organic reactive intermediates. During his graduate tenure, he was trained in computational chemistry, organic synthesis, and photochemistry, and published 13 first-authored papers, 8 of which appeared in the Journal of the American Chemical Society (JACS). He had three years of postdoctoral training with Dr. Joseph DeSimone at the University of North Carolina at Chapel Hill. As a postdoc, he gained extensive training in drug delivery, cell biology and preclinical models, and invented a novel traceless crosslinker for nanoparticle fabrication, licensed by Liquidia Technologies, Inc.
Read More
Dr. Jin Wang obtained his Ph.D. degree in Organic Chemistry from the Ohio State University with Dr. Matthew Platz in 2007, where he applied ultrafast spectroscopy to study organic reactive intermediates. During his graduate tenure, he was trained in computational chemistry, organic synthesis, and photochemistry, and published 13 first-authored papers, 8 of which appeared in the Journal of the American Chemical Society (JACS). He had three years of postdoctoral training with Dr. Joseph DeSimone at the University of North Carolina at Chapel Hill. As a postdoc, he gained extensive training in drug delivery, cell biology and preclinical models, and invented a novel traceless crosslinker for nanoparticle fabrication, licensed by Liquidia Technologies, Inc.
Dr. Wang was recruited to Baylor College of Medicine (BCM) as a tenure-track assistant professor, granted a prestigious faculty recruitment award from the Cancer Prevention and Research Institute of Texas (CPRIT), and named a CPRIT Scholar in Cancer Research. The overarching goal for his research is to develop new tools to address biological questions and new therapies to improve human health, taking advantage of his unique experience in organic chemistry, drug delivery, cell biology and preclinical studies. During his independent career, his group developed the first fluorescent probe that can quantify glutathione (GSH) concentrations in living cells.
His GSH probes have generated tremendous interest in the redox biology community, been shared with more than 50 laboratories around the globe and are becoming the gold standard to measure GSH concentrations in living cells.
He started Chemical Biology Probes LLC to further commercialize the GSH probes. Furthermore, in collaboration with Dr. Bert O’Malley’s group, he developed a new class of small molecule inhibitors, termed as SI-2, for a large, nonstructured nuclear protein--steroid receptor coactivator 3 (SRC-3), which is an important oncogene responsible for endocrine resistance, tumor proliferation, and metastasis. SI-2 can significantly inhibit primary breast tumor growth and SRC-3 protein levels in vivo. Along with Drs. O’Malley and Lonard, he co-founded Coactigon Inc. and is currently developing SI-2 derivatives that are suitable for clinical testing.
Additionally, in collaboration with Dr. Xiongbin Lu, he developed a novel antibody-drug conjugate (ADC) to target triple negative breast cancer with hemizygous TP53 loss. Recently, in collaboration with Drs. Hui Zheng and Meng Wang, he is developing novel therapies to treat Alzheimer’s disease. Thanks to the initial support from CPRIT, Dr. Wang was able to develop a diverse and multidisciplinary research program and has successfully transitioned his independent career into the fields of chemical biology and small molecule drug discovery. Dr. Wang was promoted to tenured Associate Professor of Pharmacology and Chemical Biology at Baylor College of Medicine in 2017.
Read Less
